Volunteer
Thank you for your interest in the SPARX3 study. We are actively recruiting participants for this ongoing study. Below is more information for volunteering in SPARX3.
Approximately 29 sites will enroll participants: 27 sites that cover all geographic regions of the USA and 2 sites in Canada. All sites will have a collaboration between movement disorders and exercise specialists. The sites have extensive experience conducting studies involving exercise and people with Parkinson's disease (PD).
What is SPARX3 about?
SPARX3 (NCT04284436) is a Phase 3 multi-site, randomized study of endurance treadmill exercise on changes in the signs and symptoms of PD. The goal of SPARX3 is to test whether the progression of the signs of PD is decreased in people who have not initiated medication for PD when they perform endurance treadmill exercise. 370 persons diagnosed with PD who have not yet initiated medication, age 40-80 years, will be randomly assigned to either moderate-intensity or high-intensity exercise training.
What are the research study procedures?
First, you will complete a telephone screening followed by two in-person screening visits to confirm that you meet the criteria to participate in the study. These visits consist of physical and memory/thinking assessments, a blood draw, a questionnaire to screen for depression, and a brain scan (DaTscan) that helps confirm diagnosis of PD. If you are eligible to participate in this study, you will then complete 7 additional assessment visits over the course of the 24 months, which consist of more physical and memory/thinking assessments, questionnaires, blood draws, exercise tests, and one additional brain scan. You will be randomized (like flipping a coin) to one of two exercise groups. You will be asked to exercise at a specific rate/intensity 4 days per week for approximately 30 min.
Who qualifies to volunteer in the SPARX3 study?
We are seeking individuals with PD who are willing to take part in regular treadmill exercise program 4x/week for 18 months and participate in study visits periodically for 24 months.
Volunteers must be:
40-80 years old
Diagnosed with PD within the last 3 years
Not yet taking medications for PD symptoms
Not planning to start medications for PD symptoms in the next 6 months
Not currently participating in a structured exercise program
What will volunteers be asked to do?
Physical and cognitive assessments
Blood draws at the start and end of the study
Imaging scans (DaTscan)
18 months of treadmill exercise
Regularly scheduled in-person study visits over 24 months
During this study, participants will be encouraged:
To refrain from enrolling in other studies or interventions that could affect your motor symptoms or aerobic fitness, but can continue to engage in their usual physical activities.
To refrain from enrolling in other studies that require a DaTscan™ SPECT imaging procedure as part of the study activities, with the exception of the PPMI2.0 study.
To refrain from taking dopaminergic medication unless medically necessary for the duration of the study
If you think that you may be eligible for participation please use the map and links below to find and contact the nearest clinical site for SPARX3.
If you need assistance with your particpation in the SPARX3 study contact Elizabeth Skender by email or call at 309-922-7254.
PARTICIPATING SITES
Canadian Sites 28. University of Alberta29. Wilfrid Laurier University
Clinical Sites Contacts
Alabama
University of Alabama at Birmingham
Contact: Jenna Smith
California
University of California, San Francisco
Contact: Corinna Conroy
Colorado
University of Colorado, Denver
Contact: Katherine Balfany
Florida
University of Florida
Contact: Adrienne Royster
Georgia
Illinois
Northwestern University
Contact: Garett Griffith
Rush University Medical Center
Contact: Deborah Bang
Iowa
Iowa State University
Contact: Elizabeth Stegemoller
Louisiana
Louisiana State University
Contact: Jan Hondzinski
Massachusetts
Boston University (Charles River Campus)
Contact: Jenna Zajac
Michigan
University of Michigan
Contact: Linda Rubley
Minnesota
Missouri
Washington University St. Louis
Contact: Martha Hessler
New York
New York University Langone Health
Contact: Daniella Mania
Columbia University Medical Center
Contact: Ashwini Rao
Ohio
Ohio Health
Contact: David Hinkle
University of Cincinnati
Contact: Jessica Marchbank
Cleveland Clinic
Contact: Elizabeth Jansen
Case Western Reserve & Kent State University
Contact: Angela Ridgel
Oregon
Oregon Health & Science University
Contact: Graham Harker
Pennsylvania
Texas
University of Texas Medical Brand
Contact: Summer Chapman
Utah
University of Utah
Contact: Lindsey Agnew